https://www.bmj.com/content/372/bmj.n281 Skip to main content Intended for healthcare professionals * Subscribe * My Account + My email alerts * BMA member login Login + Username * [ ] Password * [ ] Forgot your log in details? Need to activate [Login] ------------------------------------------------------------- BMA Member Log In Log in via OpenAthens Log in via your institution Edition: US * UK * South Asia * International Our company Toggle navigation The BMJ logo Site map Search Search form [ ]Search Search * Advanced search * Search responses * Search blogs Toggle top menu * covid-19 * Research + At a glance + Research papers + Research methods and reporting + Minerva + Research news * Education + At a glance + Clinical reviews + Practice + Minerva + Endgames + State of the art + What your patient is thinking + Rapid recommendations + Student * News & Views + At a glance + News + Features + Editorials + Analysis + Observations + Opinion + Head to head + Editor's choice + Letters + Obituaries + Views and reviews + Careers + Rapid responses * Campaigns + At a glance + Better evidence + Climate change + Divestment from fossil fuels + Patient and public partnership + Too much medicine + Wellbeing + The BMJ Collections * Jobs + Doctor Jobs UK + Hospital Jobs UK + GP Jobs UK + International Jobs + North America Jobs * Archive * For authors * Hosted 1. News & Views 2. Covid-19: Countries... 3. Covid-19: Countries are learning what others paid for vaccines News Covid-19: Countries are learning what others paid for vaccines BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n281 (Published 29 January 2021) Cite this as: BMJ 2021;372:n281 Read our latest coverage of the coronavirus outbreak * Article * Related content * Metrics * Responses * Peer review * Loading 1. Owen Dyer 1. Montreal A string of revelations about vaccine prices has focused attention on a practice considered normal in the drug industry but often frowned on elsewhere: charging different prices to different customers for the same product. South Africa's government found itself on the defensive this week after a senior health official revealed that 1.5 million doses of the Oxford and AstraZeneca vaccine just purchased for use among health workers would cost $5.25 (PS3.84; EUR4.32) a dose, more than twice what the European Union is paying at $2.15. The EU figure is known because Belgium's budget secretary inadvertently revealed the EU's negotiated prices for every major vaccine on Twitter last month.1 The EU had undertaken to keep the prices confidential in return for discounts. South Africa's deputy director general of health, Anban Pillay, said his government had been told that $5.25 was the set price for a country classified by the World Bank as upper-middle income. "The explanation we were given for why other high-income countries have a lower price is that they have invested in the [research and development], hence the discount," he added. That principle has also been applied to the biggest players. The EU financially supported the development of the BioNTech and Pfizer vaccine and has obtained a lower price per dose ($14.70 than the US ($19.50). The Moderna vaccine's development was subsidised by the US government, and it will cost the US about $15 a dose, while the EU is paying $18. The Oxford-AstraZeneca vaccine is much cheaper, although neither the UK nor the US can match the EU's $2.15 deal: they are expecting to pay about $3 and $4, respectively, per dose. The Johnson & Johnson vaccine, expected to announce phase III results imminently, is also much cheaper, costing the EU $8.50, with each dose going twice as far as the other brands, since it is a single shot vaccine. AstraZeneca and Johnson & Johnson have committed to not making a profit from the pandemic, while Moderna and Pfizer did not. AstraZeneca reserved the right, however, to declare the pandemic phase over and take profits from later vaccine sales. Vaccine prices are only one factor in the cost of immunisation campaigns. Of the PS11.7bn that the UK expects to spend on its vaccination programme, PS2.9bn buys vaccines, securing 267 million doses of five different types, according to the National Audit Office.2 Even the priciest vaccines repay their cost many times over in economic growth from a reopening economy. Affluent governments could well be tempted to bid higher if supplies tighten. Israel, which is on course to vaccinate all its citizens before any other country--having denied responsibility for vaccinating the Palestinians of the Occupied Territories--this month acknowledged paying $23.50 per dose on average to Pfizer and Moderna to obtain early shipments. Even at this high price, vaccinating the entire population of Israel costs the economy only as much as two days of lockdown. Uniquely, Israel agreed to give Pfizer anonymised health data from all of its citizens as part of the deal. Africa secures doses For South Africa, more troubling than the high dose cost has been an inability to secure enough vaccine. The government planned to vaccinate 40 million of its 58.5 million people but has only enough vaccine on order for 10 million. Covax, the World Health Organization's multilateral vaccine distribution programme, has set aside 600 million doses for Africa, enough to vaccinate a quarter of the continent's 1.2 billion population. But South Africa's status as an upper-middle income nation makes it ineligible for Covax assistance. At a 26 January virtual meeting of the World Economic Forum, the country's president, Cyril Ramaphosa, called on rich nations to give up their surplus doses, noting that "some countries even acquired up to four times what their population needs." On 28 January the African Union of 55 countries announced that it had secured 400 million extra doses of the Oxford-AstraZeneca vaccine, bringing its total order to 670 million. South Africa is likely to be a key beneficiary. Africa now has enough vaccine ordered to vaccinate half its population. The UK has ordered enough to theoretically vaccinate about three times its population. Rich nations would reap huge economic benefits if they paid the roughly $27bn needed to fully fund the COVAX programme to vaccinate populations of developing nations, concluded a study commissioned by the International Chamber of Commerce Research Foundation.3 Failure to vaccinate those nations would cost the global economy up to $9.2 trillion, the report found, with half of that cost falling on wealthy nations. WHO's secretary general, Tedros Adhanom Ghebreyesus, commented, "I believe the world faces a catastrophic moral failure in equal access to the tools to combat the pandemic. This research shows a potentially catastrophic economic failure." This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. https://bmj.com/coronavirus/usage References 1. | De Bleeker E. Deleted tweet showing EU vaccine prices. 17 Dec 2020. https://www.hln.be/binnenland/ zoveel-gaan-we-betalen-voor-de-coronavaccins-staatssecretaris-zet-confidentiele-prijzen-per-ongeluk-online~a3dceef4 /180355293. 2. | National Audit Office. Investigation into preparations for potential COVID-19 vaccines. 14 Dec 2020. https://www.nao.org.uk/ wp-content/uploads/2020/12/ Investigation-into-preparations-for-potential-COVID-19-vaccines.pdf . 3. | Cakmakli CC, Demiralp S, Kalemli-Ozcan S, et al. The economic case for global vaccinations: an epidemiological model with international production networks. 25 Jan 2021. https:// iccwbo.org/publication/the-economic-case-for-global-vaccinations. View Abstract * Tweet Widget * Facebook Like See other articles in issue 8278 Article tools PDF0 responses * Respond to this article * Print * Alerts & updates Article alerts Please note: your email address is provided to the journal, which may use this information for marketing purposes. Log in or register: Username * [ ] Password * [ ] [Log in] Register for alerts If you have registered for alerts, you should use your registered email address as your username * Citation tools Download this article to citation manager Owen Dyer Dyer O. Covid-19: Countries are learning what others paid for vaccines BMJ 2021; 372 :n281 doi:10.1136/bmj.n281 + BibTeX (win & mac)Download + EndNote (tagged)Download + EndNote 8 (xml)Download + RefWorks Tagged (win & mac)Download + RIS (win only)Download + MedlarsDownload Help If you are unable to import citations, please contact technical support for your product directly (links go to external sites): + EndNote + ProCite + Reference Manager + RefWorks + Zotero * Request permissions * Author citation * Articles by Owen Dyer * Add article to BMJ Portfolio Email to a friend Forward this page Thank you for your interest in spreading the word about The BMJ. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * [ ] Your Email * [ ] Send To * [ ] [ ] [ ] You are going to email the following Covid-19: Countries are learning what others paid for vaccines Your Personal Message [ ] [ ] [ ] CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. [Send] * UK jobs * International jobs Loading Crewkerne Health Centre: GP Opportunity at Crewkerne Health Centre The Hurley Group: Salaried GP opportunities available The Hurley Group: Salaried GP Hillview Surgery: Salaried GP BMA: Non-exective Directors x2 View more [CROSSMARK_Color_hori] This week's poll Read related article See previous polls Back to top Follow us on * Twitter * Facebook * YouTube * Pinterest * RSS Content links * Collections * Health in South Asia * Women's, children's & adolescents' health * Zika virus * Research * Education * News and views * BMJ Opinion * Rapid responses * Archive About us * About us * Editorial staff * BMJ in the USA * BMJ in South Asia * Advisers * Policies * Submit your paper Resources * Authors * Reviewers * BMA members * Readers * Subscribers * Advertisers and sponsors * Media * Recruiters Explore BMJ * Our company * BMJ Careers * BMJ Learning * BMJ Masterclasses * BMJ Journals * BMJ Student * Academic edition of The BMJ * BMJ Best Practice * The BMJ Awards My account * Email alerts * Activate subscription Information * Contact us * Complaints * Cookie settings * Cookie Policy * Privacy policy * Website T&Cs * Revenue Sources * HighWire Press * Sitemap Copyright (c) 2021 BMJ Publishing Group Ltd Jing ICPBei 15042040Hao -3 *